RT Journal Article SR Electronic T1 High-throughput splicing assays identify missense and silent splice-disruptive POU1F1 variants underlying pituitary hormone deficiency JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.02.04.21249469 DO 10.1101/2021.02.04.21249469 A1 Gergics, Peter A1 Smith, Cathy A1 Bando, Hironori A1 Jorge, Alexander A. L. A1 Rockstroh-Lippold, Denise A1 Vishnopolska, Sebastian A1 Castinetti, Frederic A1 Maksutova, Mariam A1 Carvalho, Luciani Renata Silveira A1 Hoppmann, Julia A1 Mayer, Julian Martinez A1 Albarel, Frédérique A1 Braslavsky, Debora A1 Keselman, Ana A1 Bergadá, Ignacio A1 Martí, Marcelo A1 Saveanu, Alexandru A1 Barlier, Anne A1 Jamra, Rami Abou A1 Guo, Michael H. A1 Dauber, Andrew A1 Nakaguma, Marilena A1 Mendonça, Berenice B A1 Ozel, A Bilge A1 Fang, Qing A1 Ma, Qianyi A1 Li, Jun Z. A1 Brue, Thierry A1 Millán, María Ines Pérez A1 Kitzman, Jacob O. A1 Arnhold, Ivo JP A1 Pfaeffle, Roland A1 Camper, Sally A. YR 2021 UL http://medrxiv.org/content/early/2021/02/08/2021.02.04.21249469.abstract AB Pituitary hormone deficiency occurs in ∼1:4,000 live births. Approximately 3% of the cases are due to mutations in the alpha isoform of POU1F1, a pituitary-specific transcriptional activator. We found four separate heterozygous missense variants in unrelated hypopituitarism patients that were predicted to affect a minor isoform, POU1F1 beta, which can act as a transcriptional repressor. These variants retain repressor activity, but they shift splicing to favor the expression of the beta isoform, resulting in dominant negative loss of function. Using a high throughput splicing reporter assay, we tested 1,080 single nucleotide variants in POU1F1. We identified 113 splice disruptive variants, including 23 synonymous variants. We evaluated separate cohorts of hypopituitarism patients and found two different synonymous splice disruptive variants that co-segregate with hypopituitarism. This study underlines the importance of evaluating the impact of variants on splicing and provides a catalog for interpretation of variants of unknown significance in the POU1F1 gene.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Institutes of Health (R01HD097096 to SAC), the Japan Society for Promotion of Science (HB), Grant 2013/03236-5 from the São Paulo Research Foundation (FAPESP) (IJPA), a grant from Pfizer (RP), and the Argentinean National Agency of Scientific and Technical Promotion, PICT 2016-2913 and PICT 2017-0002 (MIPM). There was no third party funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies were approved by ethical committees: the local Comite de Eticae Pesquisa da Faculdade de Medicina da Universidade de Sao Paulo (CEP-FMUSP) and the national Comite nacional de etica em pesquisa (CONEP) CAAE, 06425812.4.0000.0068; the Ethics Committee of the Faculty of Medicine, University of Leipzig (UL), Karl-Sudhoff-Institute for Medical History and Natural Sciences, Kaethe-Kollwitz-Strasse 82, 04109 Leipzig, Germany; and the Comite de Etica en Investigacion (Research Ethics Committee) of the Hospital de Ninos Ricardo Gutierrez (HNG), Gallo 1330, Ciudad autonoma de Buenos Aires, Argentina (CEI No. 16.06). The GENHYPOPIT network collected anonymized information in a database declared to health authorities in accordance with local regulations at Aix-Marseille Universite (AMU) - Conception Hospital (Assistance Publique - Hopitaux de Marseille, AP-HM), and a declaration was made to the National Commission for Data Protection and Liberties (CNIL-France): 1991429 v 0. The University of Michigan Institutional Review Board (UM) found the study exempt because patient DNA samples were anonymized before exome sequencing at UM.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be posted on GEO and Github